Prophylactic Antibiotic Use in Transarterial Chemoembolization for Hepatocellular Carcinoma

• Status: Recruiting
• Trial end date: 2023-12-26
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to determine the effectiveness of prophylactic antibiotic use for TACE and occurrence of postoperative liver abscess.

There would be two comparison groups. Current standard of care treatment at PKLI&RC (as per local guidelines) would be given to all patients receiving TACE for the intervention group or 'antibiotic group' (i.e., Inj. Ceftriaxone 1g, intravenous × stat). While no antibiotic would be given to the 'no antibiotic group'.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nadeem Iqbal
• Collaborators: Ahmad Zia; Muhammad Junaid Tahir
• Treatments: Ceftriaxone

Criteria

Inclusion Criteria:

1. Diagnosis of primary liver cancer or hepatocellular carcinoma.

2. Patients receiving TACE in PKLI & RC.

3. Patients giving informed consent.

Exclusion Criteria:

1. Receiving two or more TACE during the same hospitalization

2. Use of any antibiotics other than the prophylactic antibiotic in 48hours prior to TACE

3. Known hypersensitivity to specified antibiotic used in the study

4. Incomplete or missing laboratory investigations and data

5. Taking Sorafenib before TACE

6. TACE combined with ablation or immunetherapy

7. Tumor size >10 cm

8. Portal vein thrombosis

9. Dilated biliary channels on CT scan / Billiary invasion by tumor